Sickle cell disease in sub-Saharan Africa
Haemoglobin disorders are inherited blood diseases that affect how oxygen is carried in the body. Haemoglobin disorders fall into two main categories: sickle-cell disease and thalassaemias.
• Sickle-cell disease is characterized by a modification in the shape of the red blood cell from a smooth, donut-shape into a crescent or half moon shape. The misshapen cells lack plasticity and can block small blood vessels, impairing blood flow. This condition leads to shortened red blood cell survival, and subsequent anaemia, often called sickle-cell anaemia. Poor blood oxygen levels and blood vessel blockages in people with sickle-cell disease can lead to chronic acute pain syndromes, severe bacterial infections, and necrosis (tissue death).
• Thalassaemias are also inherited blood disorders. People with thalassaemia are not able to make enough haemoglobin, which is found in red blood cells. When there is not enough haemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs then become starved for oxygen and are unable to function properly. There are two major types of thalassaemia, alpha and beta, which are named for the two protein chains that make up normal haemoglobin. Alpha and beta thalassaemia have both mild and severe forms.
Sickle cell disease (SCD), or sickle cell anaemia, is a major genetic disease that affects most countries in the African Region. In sickle cell disease, the normal round shape of red blood cells become like crescent moons. Round red blood cells can move easily through the blood vessels but sickled shaped cells interconnect and can result in blood clots. These blood clots can cause extreme pain in the back, chest, hands and feet. The disrupted blood flow can also cause damage to bones, muscles and organs. People with sickle cell disease often feel weak, tired and look pale. The whites of the eyes and skin often have a yellowish tint. Environmental factors often play a role in the occurrence of painful attacks. Common triggers include cold temperatures, dehydration, excessive amounts of exercise and tobacco smoke. Other triggers such as plane flights and high altitudes can also trigger an attack.
In the Region, the majority of children with the most severe form of the disease die before the age of 5, usually from an infection or severe blood loss. In countries such as Cameroon, Republic of Congo, Gabon, Ghana and Nigeria the prevalence is between 20% to 30% while in some parts of Uganda it is as high as 45%.
Haemoglobin disorders are inherited from parents in much the same way as blood type, hair colour and texture, eye colour and other physical traits.
Sickle-cell disease and severe forms of thalassaemia (thalassaemia major) can occur only when both parents are carriers of trait genes for the particular condition. A child who inherits two of the same trait genes – one from each parent – will be born with the disease. However, a child of two carriers has only a 25% chance of receiving two trait genes and developing the disease, and a 50% chance of being a carrier. Most carriers lead completely normal, healthy lives.
Haemoglobin disorders can be effectively reduced through a strategic balance of disease management and prevention programmes.
Newborn screening
— Diagnosis of SCD early in life improves survival. Early diagnosis allows for initiation of well-established public health measures for primary prevention including penicillin prophylaxis, routine childhood vaccinations, parental education about prompt medical management for fever, and detection of splenic sequestration. These strategies have been demonstrated to minimize morbidity and improve outcomes and are the basis for newborn screening for SCD being performed in every state in the United States.
However, laboratory methods for diagnosis require an infrastructure that is not routinely available in sub-Saharan Africa. Only a few centers in sub-Saharan Africa are able to initiate newborn screening and deliver comprehensive health care at an early age due to the costs associated with such programs.The importance of newborn screening in reducing mortality has been demonstrated in the following studies:
● United States – Reduced mortality was reported in a review that summarized 10 years of experience using newborn screening in the state of California from 1975 to 1985 Of over 80,000 newborns screened, SCD was diagnosed in approximately 0.1 percent and sickle cell trait in 2.6 percent. Mortality in the 81 patients diagnosed with SCD by newborn screening (coupled with education about detecting splenic sequestration and early warning signs of infection) was 1.8 percent over seven years, dramatically lower than the 8 percent mortality in a comparison group of patients diagnosed after three months of age.
● Africa – In a program in Kenya that identified infants with and without SCD in infancy and then followed them over several years, the survival difference was about the same in those with hemoglobin SS and normal hemoglobin and much higher in children with hemoglobin AS.
As an example, in Nigeria the rate of SCD is estimated to be 300 per 1000 births.
No federal newborn screening program for SCD has been established for any country in sub-Saharan Africa despite the clear economic and humanitarian basis for such programs; Ghana is close to implementing such a program.
Childhood presentation
Most individuals in sub-Saharan Africa with SCD are not diagnosed by newborn screening and present with symptoms during childhood, at a mean age of two years. Very few are diagnosed earlier (eg, during infancy). The most common presentations for previously undiagnosed SCD include dactylitis at six months to one year and splenic sequestration in the second year of life. Thus, we believe that children presenting with either dactylitis or splenic sequestration should be evaluated for SCD with a complete blood count and hemoglobin analysis.
INFECTIONS
Bacterial infections — The risk of bacterial infection is dramatically increased in SCD, particularly for children less than five years of age
Bacterial infections (prophylaxis) —
The two major interventions to reduce the incidence of bacterial infections are vaccinations, especially against encapsulated organisms, and penicillin prophylaxis. However, the availability of vaccinations is limited, and routine penicillin prophylaxis is unavailable in the majority of medical centers in sub-Saharan Africa [ 33].
● Vaccinations – We strongly believe that integration of routine childhood immunization against Streptococcus pneumoniae and Haemophilus influenzae into the standard of care in sub-Saharan African countries could substantially affect survival of children with SCD
● Penicillin – Penicillin prophylaxis is highly effective in preventing infection. We recommend monthly intramuscular penicillin prophylaxis rather than daily oral penicillin.
Use of intramuscular penicillin also avoids the requirement for refrigeration of oral penicillin suspension, which may be challenging in low-income countries. We continue penicillin prophylaxis until age five years if possible, and some pediatricians may elect to continue for a longer period of time.
However, routine penicillin prophylaxis is unavailable in the majority of medical centers.
MALARIA —
Malaria infection in individuals with homozygous sickle hemoglobin S (HbSS) is one of the most common causes of vaso-occlusive pain, one of the leading reasons for hospitalization, and one of the most important causes of mortality in sub-Saharan Africa, despite the evidence that HbSS improves mortality in children <5 years . The first five years of life are the highest risk for malaria because of the lack of immunity, regardless of the hemoglobin type (hemoglobin SS, AS, or AA)
Malaria (prophylaxis) — Strategies for control and prevention of malaria include mosquito control, personal protection, and antimalarial prophylaxis.
In children with SCD, malaria infection is associated with severe hemolysis and typically presents with fever, brown-colored urine, acute fatigue, and vaso-occlusive pain. In adults with SCD, malaria infection causes a similar clinical presentation and is associated with vaso-occlusive pain episode.
VASO-OCCLUSIVE EVENTS
Vaso-occlusive events in SCD include acute painful episodes and organ-specific complications such as stroke, acute chest syndrome, priapism, and dactylitis.
Pain episodes — Painful episodes are a significant cause of morbidity, accounting for a large number of emergency department visits and hospital admissions.>
Dactylitis is the first presentation of pain in children with SCD. When dactylitis is present, management should be identical to those provided in high income countries. This involves supportive care that includes hydration, NSAIDs and/or opioid analgesics, and assessment for occult infection, particularly bacteremia and malaria. Hydroxyurea has been demonstrated to reduce the frequency of acute painful events in SCD
Acute chest syndrome — Acute chest syndrome (ACS) is one of the life-threatening vaso-occlusive complications seen both in children and adults with SCD. ACS is associated with high mortality rate, especially in sub-Saharan Africa and other low-income countries.
Splenic sequestration — Splenic sequestration is a potentially life-threatening complication that occurs when blood pools rapidly in the spleen. It is characterized by an acute fall in the hemoglobin level accompanied by a rapidly enlarging spleen or liver (greater than 2 cm increase from the steady state level) and increased reticulocytosis above the steady state level.
Management of splenic sequestration in resource-poor settings involves hospital admission with urgent laboratory testing (complete blood count, pretransfusion testing) and red blood cell transfusion at a dose of 10 mL/kg.
In contrast, there is little evidence that regular blood transfusion or hydroxyurea therapy reduces the risk of splenic sequestration.
Stroke —
Children with SCD are at increased risk of neurological complications including overt strokes and silent cerebral infarcts, both of which are associated with increased morbidity and mortality. Approximately 11 percent of children with SCD will have a stroke before age 14, and without secondary prevention more than half of these will have recurrent stroke within two years of the initial stroke.
Acute management (stroke) —
The standard radiologic imaging to determine the type of stroke is not available in the majority of medical centers in sub-Saharan Africa. Thus, diagnosis of stroke is made by clinical evaluation.
The standard management approach, including immediate blood transfusion followed by exchange blood transfusion to maintain the hemoglobin S (HbS) percentage below 30 percent, is not available in the majority of medical centers in sub-Saharan Africa.
Acute stroke management in resource-poor settings includes the following:
●Immediate admission into the hospital
●Assessment of vital signs
●Examination to assess the extent and severity of central nervous system involvement
●Maintenance of airway and breathing, and oxygen administration
●Treatment of fever with antipyretics and presumptive treatment of infection with antibacterial and antimalarial agents until results of cultures are available
●Intravenous fluids
●Simple blood transfusion when available
●Where available, simple blood transfusion is followed by modified- or full-exchange blood transfusion, performed either manually or automated [ 68,69]
As noted above, imaging of the brain is not routinely performed.
Prevention (stroke) —
Regardless whether children live in low- or high-income settings, the risk of stroke in children with SCA is approximately 11 percent by 18 years of age. Further, once a child with SCA has a stroke, without treatment, approximately 50 percent will have second stroke
For secondary stroke prevention in high-resource settings, hydroxyurea was not as effective as regular transfusion therapy; however, hydroxyurea is superior to supportive care alone. Regular blood transfusion therapy for stroke prevention is not an option for children with SCD in sub-Saharan Africa for several reasons including but not limited to the high cost of transfusion, unavailability of blood, and unsafe transfusion practices
Orthopedic complications —
Orthopedic complications are one of the most common long-term sources of morbidity in adults with SCD, typically avascular necrosis of the head of the femur.
The presentation is characterized by pain in the hips, limping, and progressive deformity of the hip joint. In low-income countries, management includes prolonged analgesics, which only provide temporal relief of pain. The standard treatment for these patients should include physical therapy and surgical interventions. Regrettably in sub-Saharan Africa, only a few centers can provide surgical interventions, due to several reasons including cost, inadequate manpower, and lack of expertise and equipment.
Hydroxyurea —
Hydroxyurea has become the standard of care for reducing the risk of vaso-occlusive and other complications in children and adults with SCD in high-income countries, based on demonstration of its efficacy in reducing complications in all age groups (including infants). In high-income countries, hydroxyurea is administered in a maximum tolerated dose strategy that requires intensive monitoring (clinical and laboratory) with frequent and ongoing dose adjustments.
Hydroxyurea is not used as often in very young children in Africa, primarily due to concerns about the higher rate of mortality and life-threatening bacterial and malarial infection in affected individuals in Africa and the unknown effect of hydroxyurea therapy.
Despite these concerns, evidence demonstrates that hydroxyurea is effective in reducing serious complications in individuals in sub-Saharan Africa, and it is hoped that these data will lead to more widespread use of this therapy.
●A large study in 2018 demonstrated that hydroxyurea can be safely administered to children in Africa with dramatic clinical benefits.
The REACH (Realizing Effectiveness Across Continents with Hydroxyurea) study enrolled 635 children with SCD in four sub-Saharan African countries (Angola, Democratic Republic of Congo, Kenya, and Uganda) to receive hydroxyurea at a fixed dose of 15 or 20 mg/kg daily for six months, followed by dose escalation to maximum tolerated dose, defined in this study as mild bone marrow suppression.
• Efficacy – Hydroxyurea dramatically reduced vaso-occlusive and other sickle cell complications compared with pre-treatment parameters obtained at the time of screening. Examples of reductions in death and complications include the following (expressed per 100 patient-years):
• Safety – Therapy was well tolerated, with the expected hematologic toxicities used for dose adjustments. There were no significant increases in serious treatment-related adverse events.
• Dosing – Dose escalation after the first six months of treatment was done by increasing the daily dose by 2.5 to 5 mg/kg/day every two months until an ANC of <4000/microL was reached. The mean dose was 22.5 mg/kg/day (mean doses in different countries ranged from 18.9 to 25.3 mg/kg/day), and the mean time to reach this dose was 11 months.
Dosing of hydroxyurea can be done either by a fixed dose or by dose titration to mild neutropenia (absolute neutrophil count [ANC] <4000/microL, as done in the REACH trial). If cost and ease of administration are a concern, fixed dose is preferred because it requires less intensive monitoring. Doses are as follows:
●Children – 20 mg/kg/day
●Adults – 15 mg/kg/day
Blood transfusion —
Blood transfusion is used in the management and prevention of several complications of SCD in children and adults in resource-rich countries. However, transfusion presents major challenges in sub-Saharan Africa These challenges include the unavailability of blood, the high cost associated with receiving blood transfusions, and in some areas a high risk of transfusion-associated infections . Moreover, the majority of medical centers in sub-Saharan Africa rely on family replacement donation, which carries a higher risk of bloodborne infections than voluntary donors . Other major difficulties that have been reported include red blood cell alloimmunization due to non-standardized blood banking systems and transfusion reactions.
In the few African centers where blood transfusion is available and chronic blood transfusion is practiced, the risk of iron overload and the exorbitant cost of iron chelation is not affordable to the majority of families As an example, the estimated annual cost of conducting chronic blood transfusion including iron chelation for a single patient in the United States is often over USD $50,000, with even higher costs associated with the oral iron chelation.
Hematopoietic cell transplantation —
Allogeneic hematopoietic cell transplantation (HCT) is the only available cure for SCD This involves replacing the patient’s bone marrow hematopoietic stem cells containing the sickle mutation with hematopoietic stem cells containing a normal beta-globin genotype (either heterozygous or homozygous).
HCT is rarely performed in low-income countries in Africa, despite the advancements made in high-income countries.
Conclusion
The most cost-effective strategy for reducing the burden of haemoglobin disorders is to complement disease management with prevention programmes. Inexpensive and reliable blood tests can identify couples at risk for having affected children.
This screening is especially opportune before marriage or pregnancy, allowing couples to discuss the health of their family. Subsequent genetic counselling informs trait carriers of risks that the condition may be passed along to their children, the treatment needed, if affected by a haemoglobin disorder, and the possible options for the couple.
Prenatal screening of genetic diseases raises specific ethical, legal and social issues that require appropriate consideration.
Dr. Pietro Sodani, Haematologist
References
1. Ansong D, Akoto AO, Ocloo D, Ohene-Frempong K. Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis 2013; 5:e2013062.
2. Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy 2005; 4:239.
3. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.
4. Tshilolo L, Kafando E, Sawadogo M, et al. Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health 2008; 122:933.
5. Kadima BT, Gini Ehungu JL, Ngiyulu RM, et al. High rate of sickle cell anaemia in Sub-Saharan Africa underlines the need to screen all children with severe anaemia for the disease. Acta Paediatr 2015; 104:1269.
6. Odunvbun ME, Okolo AA, Rahimy CM. Newborn screening for sickle cell disease in a Nigerian hospital. Public Health 2008; 122:1111.
7. Obaro S. Pneumococcal infections and sickle cell disease in Africa: does absence of evidence imply evidence of absence? Arch Dis Child 2009; 94:713.
8. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 2009; 374:1364.
9. Konotey-Ahulu FI. Management of patients with sickle-cell disease. Lancet 1972; 2:772.
10. Aluoch JR. Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Trop Med Int Health 1997; 2:568.
11. Ikeh EI, Teclaire NN. Prevalence of malaria parasitaemia and associated factors in febrile under-5 children seen in Primary Health Care Centres in Jos, North Central Nigeria. Niger Postgrad Med J 2008; 15:65.Ambe JP,
12. Mava Y, Chama R, et al. Clinical features of sickle cell anaemia in northern nigerian children. West Afr J Med 2012; 31:81.
13. Ezeonwu B, Chima O, Oguonu T, et al. Morbidity and mortality pattern of childhood illnesses seen at the children emergency unit of federal medical center, asaba, Nigeria. Ann Med Health Sci Res 2014; 4:S239.
14. Komba AN, Makani J, Sadarangani M, et al. Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. Clin Infect Dis 2009; 49:216
15. Lagunju IA, Brown BJ, Sodeinde OO. Chronic blood transfusion for primary and secondary stroke prevention in Nigerian children with sickle cell disease: a 5-year appraisal. Pediatr Blood Cancer 2013; 60:1940.
16. Tagny CT, Mbanya D, Tapko JB, Lefrère JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion 2008; 48:1256.
17. Bates I, Manyasi G, Medina Lara A. Reducing replacement donors in Sub-Saharan Africa: challenges and affordability. Transfus Med 2007; 17:434.
18. Mbanya DN, Tayou C. Blood safety begins with safe donations: update among blood donors in Yaounde, Cameroon. Transfus Med 2005; 15:395.
19. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007; 47:1820.
20. Afro.who, sickle-cell-disease in Africa.
21. Sickle cell disease in sub-Saharan Africa.Authors: Michael R DeBaun, MD, MPH, Najibah A Galadanci, MBBS, MPH
22. Konotey-Ahulu FI. Management of patients with sickle-cell disease. Lancet 1972; 2:772.
Posted on November 20, 2019
Piero Petricca
